Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals for $7.2 billion, marking a significant expansion into cannabis-derived medicines and creating a leader in neuroscience therapeutics.

Rhythm Pharmaceuticals reported a 48% year-over-year increase in global net revenue, reaching $33.3 million in Q3 2024, driven by IMCIVREE sales for Bardet-Biedl Syndrome (BBS).

Jazz Pharmaceuticals secures exclusive development and commercialization rights to zanidatamab, a novel HER2-targeted bispecific antibody, in a deal potentially worth $1.76 billion plus royalties.

CStone Pharmaceuticals will present clinical data on CS5001, an anti-ROR1 ADC, at the American Society of Hematology Annual Meeting.

Crinetics Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for paltusotine, a novel oral somatostatin receptor type 2 agonist, for treating acromegaly.

CANbridge Pharmaceuticals has received NMPA approval for velaglucerase-beta (Gaurunning), China's first domestically developed enzyme replacement therapy for Type I and III Gaucher disease in patients aged 12 and above.

ARS Pharmaceuticals активно продвигает Neffy (назальный спрей эпинефрина) в США в качестве первого и единственного безъигольного лечения анафилаксии.

Gildeuretinol (ALK-001) receives Rare Pediatric Disease and Fast Track designations from the FDA, highlighting the urgent need for Stargardt disease treatments.

Aridis Pharmaceuticals has executed an agreement to sell AR-501, a therapeutic for chronic bacterial lung infections in cystic fibrosis, for $6.5 million plus royalties.

KalVista Pharmaceuticals presented data at the Bradykinin Symposium 2024, highlighting sebetralstat's consistent efficacy and safety in treating hereditary angioedema (HAE) attacks.

Jacobio Pharmaceuticals has commenced a clinical trial for a new cancer drug, marking a significant step in their oncology program.

Hemogenyx Pharmaceuticals has commenced patient recruitment for its Phase I clinical trial of a novel treatment for acute myeloid leukemia (AML).

Arrowhead Pharmaceuticals announced FDA acceptance of its New Drug Application for plozasiran to treat familial chylomicronemia syndrome (FCS), with a PDUFA date of November 18, 2025.

Brilacidin, a defensin-mimetic compound developed by Innovation Pharmaceuticals, demonstrates potential applications across multiple conditions including COVID-19, bacterial infections, and inflammatory diseases.

Tonix Pharmaceuticals collaborates with KEMRI to develop TNX-801, a live-virus vaccine, for mpox prevention.

Granules Pharmaceuticals has received FDA approval for its ANDA for Lisdexamfetamine Dimesylate Chewable Tablets, used to treat ADHD and BED.

The U.S. Food and Drug Administration has granted approval for Telix Pharmaceuticals' new drug application for their prostate cancer imaging agent, offering improved diagnostic capabilities for clinicians.

Amylyx reported positive topline data from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, showing improvement or stabilization across key disease measures.

60 Degrees Pharma received IRB approval for an expanded access study of tafenoquine to treat persistent babesiosis in immunocompromised patients.

X4 Pharmaceuticals' Marketing Authorization Application (MAA) for mavorixafor to treat WHIM syndrome is under EMA review, potentially the first EU-approved drug for the condition.